Central Retinal Artery Occlusion (CRAO)

The central retinal artery is a branch of the ophthalmic artery and supplies the retina.

Central retinal artery occlusion (CRAO) refers to blockage of the central artery of the retina, which leads to a profound and acute loss of vision. It is also associated with increased risk of the development of cerebral stroke and ischemic heart disease.

It is due to the development of atherosclerosis in the systemic and ocular arteries.

CRAO is usually caused by thromboembolism due to atherosclerotic plaques in the carotid artery, though it may also arise from carotid artery stenosis or from plaques in the coronary vessels.

Ophthalmic Emergency: Central Retinal Artery Occlusion - Quick Review

Types of CRAO

CRAO may be of the following types:

  • Non-arteritic permanent: this is the most common type, seen in two of every three patients. Risk factors include:
    • Hypertension
    • Diabetes mellitus
    • Atherosclerotic disease of the carotid or coronary arteries
    • Transient ischaemic attacks (TIAs) or cerebrovascular accidents
    • Smoking
    • v=Vascular disease such as the connective tissue disorders, use of oral contraceptives, or myeloproliferative disease, in younger patients
  • Non-arteritic transient: similar to a TIA, this condition is associated with an acute but transient attack of visual loss due to short-lived occlusion of the central retinal artery which is quickly and spontaneously relieved. Serotonin-induced vasospasm may be one way in which this type of occlusion occurs, because platelets present in association with atherosclerotic plaques release this neurochemical.
  • Non-arteritic CRAO with cilioretinal sparing: an additional cilioretinal artery is found in almost half of all individuals, and supplies the retina to a variable extent. With the onset of CRAO, the presence of this artery may spare the retina from extensive damage if it supplies a sizable area of the retina.
  • Arteritic CRAO due to giant cell arteritis – this is found in about 5% of cases.

Diagnosis

The diagnosis of CRAO is based upon the following clinical features:

  • A history of loss of vision in one eye, not associated with pain, and of sudden onset
  • Eliciting risk factors for CRAO as listed above
  • Findings of the physical examination such as atrial fibrillation which predisposes to thromboembolic phenomena, and scalp tenderness in temporal arteritis
  • Findings from an ocular examination such as posterior pole retinal opacity in approximately 58% of patients, while cherry-red spot is seen in 9 of every 10 individuals. Retinal arterial attenuation is found in a third of patients.  
  • Results of ocular testing and other tests: fundoscopy may show the presence of thrombi in the vessels, the appearance of which varies with the type of clots. The type of vascular disorder may also be suggested as hypertensive retinopathy or pre-retinal arterial loops. Fluorescein angiography of the fundus shows the cattle-trucking sign of the blood column inside the branches of the retinal artery, with impaired filling of the involved blood vessels.

Management

The condition is treated in a variety of ways but none have been shown to be more effective than placebo. Available options for acute phase management include:

  • Isosorbide dinitrate sublingually
  • Systemic pentoxiffylline
  • Carbogen inhalation
  • Hyperbaric oxygen
  • Ocular massage
  • Intravenous acetazolamide
  • Intravenous mannitol
  • Paracentesis of the anterior chamber
  • Systemic corticosteroids such as methylprednisolone
  • Eyeball compression
  • Tissue plasminogen activator to dissolve the clots and restore retinal circulation

Subacute phase management is concerned with the prevention of neovascularization and associated complications such as further visual loss.

Future prevention of cerebrovascular accidents or recurrent occlusive events in the eye is also initiated.

References

Further Reading

Last Updated: Feb 26, 2019

Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2019, February 26). Central Retinal Artery Occlusion (CRAO). News-Medical. Retrieved on November 23, 2024 from https://www.news-medical.net/health/Central-Retinal-Artery-Occlusion-(CRAO).aspx.

  • MLA

    Thomas, Liji. "Central Retinal Artery Occlusion (CRAO)". News-Medical. 23 November 2024. <https://www.news-medical.net/health/Central-Retinal-Artery-Occlusion-(CRAO).aspx>.

  • Chicago

    Thomas, Liji. "Central Retinal Artery Occlusion (CRAO)". News-Medical. https://www.news-medical.net/health/Central-Retinal-Artery-Occlusion-(CRAO).aspx. (accessed November 23, 2024).

  • Harvard

    Thomas, Liji. 2019. Central Retinal Artery Occlusion (CRAO). News-Medical, viewed 23 November 2024, https://www.news-medical.net/health/Central-Retinal-Artery-Occlusion-(CRAO).aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.